argenx Outlines 'Vision 2030' with Focus on Autoimmune Disease Therapies
核心洞察
argenx will present its 'Vision 2030' at its R&D Day, focusing on expanding its reach to 50,000 patients with severe autoimmune diseases.
The company plans to broaden its leadership in myasthenia gravis (搜索) (MG) and chronic inflammatory demyelinating polyneuropathy (搜索) (CIDP) with VYVGART and empasiprubart.
Phase 2 data in Sjogren’s disease (搜索) and multifocal motor neuropathy (搜索) (MMN) support the advancement of efgartigimod and empasiprubart to Phase 3 development.
argenx SE is set to unveil its 'Vision 2030' at its R&D Day on July 16, 2024, in New York City, outlining its strategy to extend its impact to 50,000 patients suffering from severe autoimmune diseases. The company's presentation will include updates from its clinical pipeline and introduce new innovative candidates, reinforcing its commitment to transforming autoimmunity treatment.
Expanding Autoimmune Portfolio
argenx's 'Vision 2030' underscores its dedication to advancing the treatment of severe autoimmune diseases through its key drugs VYVGART and empasiprubart, along with an expanding pipeline of antibody-based therapeutics. The company aims to solidify its position in treating myasthenia gravis (搜索) (MG) and chronic inflammatory demyelinating polyneuropathy (搜索) (CIDP), while also progressing its next wave of indications through late-stage development.
Clinical Data and Pipeline Updates
The R&D Day will feature recent Phase 2 datasets for efgartigimod in Sjogren’s disease (搜索) and empasiprubart in multifocal motor neuropathy (搜索) (MMN), supporting their advancement into Phase 3 trials. Presentations will also preview the Phase 2/3 ALKIVIA study in immune-mediated myopathies and the expansion of MG opportunities through label-enabling studies, including seronegative MG.
PC-POTS Program Discontinued
argenx announced it will not proceed with the development of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (搜索) (PC-POTS). Phase 2 ALPHA study results indicated that patients treated with efgartigimod did not show clinically meaningful improvement compared to placebo, based on the total Malmö POTS symptom (MaPS) score and COMPASS31. The company will now prioritize resources towards its other clinical trials.
Management Commentary
"argenx today is better positioned than ever before to deliver on our commitment to transform the autoimmunity treatment landscape for patients," said Tim Van Hauwermeiren, Chief Executive Officer of argenx. He emphasized the company's growth into a global innovator, delivering first-in-class medicines to over 10,000 patients and pioneering novel targets. "We look forward to sharing our 'Vision 2030', and outlining how the innovation playbook that brought us here today will power our growth and evolution as we scale the argenx innovation ecosystem."